Merrimack Pharma Plans Voluntary NASDAQ Delisting Pending Stockholder Approval for Dissolution

Merrimack Pharmaceuticals (NASDAQ: MACK) has notified NASDAQ of its intention to delist its securities, pending stockholder approval of the Plan of Dissolution at the scheduled Special Meeting on May 10, 2024. The plan entails issuing an initial liquidating cash dividend…

Read MoreMerrimack Pharma Plans Voluntary NASDAQ Delisting Pending Stockholder Approval for Dissolution

MiLaboratories, Miltenyi Biotec Forge Therapeutic Partnership

MiLaboratories, renowned for RNA immune technologies, and Miltenyi Biotec, a global biotechnology leader, join forces in a groundbreaking partnership set to transform next-generation therapies. This collaboration merges MiLaboratories’ innovative RNA kit technology for immune sequencing with Miltenyi Biotec’s extensive production…

Read MoreMiLaboratories, Miltenyi Biotec Forge Therapeutic Partnership

AndHealth Teams Up with PrimaryOne Health to Tackle Health Inequities Through In-House Specialty Care

“AndHealth Teams Up with PrimaryOne Health to Expand Specialty Care Access and Address Health Inequities” AndHealth and PrimaryOne Health have joined forces to offer in-house specialty care to their communities. PrimaryOne Health, known as the oldest and largest Community Health…

Read MoreAndHealth Teams Up with PrimaryOne Health to Tackle Health Inequities Through In-House Specialty Care